Sequential treatment with afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: an observational study
-
- Maximilian J Hochmair
- Department of Respiratory & Critical Care Medicine, Ludwig Boltzmann Institute of COPD & Respiratory Epidemiology, Otto Wagner Hospital, Sanatoriumstrasse 2, 1140Vienna, Austria
-
- Alessandro Morabito
- Thoracic Medical Oncology, Istituto Nazionale Tumori, ‘Fondazione G.Pascale’-IRCCS, 80131Napoli, Italy
-
- Desiree Hao
- Tom Baker Cancer Center, Cummings School of Medicine, University of Calgary, Calgary, Alberta, Canada
-
- Cheng-Ta Yang
- Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan
-
- Ross A Soo
- Department of Haematology-Oncology, National University Hospital Singapore
-
- James C-H Yang
- Department of Oncology, National Taiwan University Hospital & National Taiwan University Cancer Center, Taipei, Taiwan
-
- Rasim Gucalp
- Department of Oncology, Montefiore/Albert Einstein Cancer Center, Bronx, NY, USA
-
- Balazs Halmos
- Department of Oncology, Montefiore/Albert Einstein Cancer Center, Bronx, NY, USA
-
- Lara Wang
- Clinical Trials, Boehringer Ingelheim Taiwan Limited Taiwan
-
- Amanda Golembesky
- Epidemiology, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
-
- Angela Märten
- Medical Affairs Oncology, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
-
- Tanja Cufer
- Medical Faculty, University Clinic Golnik, University of Ljubljana, Ljubliana, Slovenia
Journal
-
- Future Oncology
-
Future Oncology 14 (27), 2861-2874, 2018-10-19
Informa UK Limited
- Tweet
Details 詳細情報について
-
- CRID
- 1361981470885137280
-
- ISSN
- 17448301
- 14796694
-
- Data Source
-
- Crossref